In 50 adults with metastatic NSCLC progressing after chemotherapy, adding single-fraction SABR to nivolumab did not improve 6-month PFS vs nivolumab alone (49% vs 44%; HR 0.68, p=0.23); response, OS and grade 3-5 AEs were similar. Closed early for slow accrual.
RCTn = 50
Kothari et al. A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)